Evidence map›Paper›PMID 29351998›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2018

Detection of Experimental and Clinical Immune Complexes by Measuring SHIP-1 Recruitment to the Inhibitory FcγRIIB.

Richard J Stopforth, Robert J Oldham, Alison L Tutt, Patrick Duriez, H T Claude Chan, Brock F Binkowski, Chad Zimprich, Dun Li, Philip G Hargreaves, Mei Cong and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Blocking TIGIT/CD155 signalling reverses CD8Journal of translational medicine · 2022
    Article
  3. Article
  4. Autoimmunity in 2018.Clinical reviews in allergy & immunology · 2019
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Richard J StopforthAntibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom.
Robert J OldhamAntibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom.ORCID 0000-0002-8007-1145
Alison L TuttAntibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom.
Patrick DuriezSouthampton Experimental Cancer Medicine/Cancer Research U.K. Centre, Protein Core Facility, Cancer Sciences Unit, Southampton General Hospital, Southampton SO16 6YD, United Kingdom.ORCID 0000-0003-1814-2552
H T Claude ChanAntibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom.ORCID 0000-0003-0530-9480
Brock F BinkowskiPromega Corp., Fitchburg, WI 53711.ORCID 0000-0001-6231-4396
Chad ZimprichPromega Corp., Fitchburg, WI 53711.
Dun LiPromega Corp., Fitchburg, WI 53711.ORCID 0000-0001-6789-0763
Philip G HargreavesPromega UK Ltd., Southampton Science Park, Southampton SO16 7NS, United Kingdom.ORCID 0000-0002-7312-5117
Mei CongPromega Corp., Fitchburg, WI 53711.
Venkat ReddyDivision of Medicine, Centre for Rheumatology, University College London, London WC1E 6JF, United Kingdom; and.
Maria J LeandroDivision of Medicine, Centre for Rheumatology, University College London, London WC1E 6JF, United Kingdom; and.
Geraldine CambridgeDivision of Medicine, Centre for Rheumatology, University College London, London WC1E 6JF, United Kingdom; and.ORCID 0000-0002-6022-6322
Anja LuxDepartment of Biology, University of Erlangen-Nuremberg, 91058 Erlangen, Germany.
Falk NimmerjahnDepartment of Biology, University of Erlangen-Nuremberg, 91058 Erlangen, Germany.
Mark S CraggAntibody and Vaccine Group, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; msc@soton.ac.uk.ORCID 0000-0003-2077-089X
Southampton General Hospital · GBPromega (United States) · USUniversity College London · GBFriedrich-Alexander-Universität Erlangen-Nürnberg · DECancer Research UK · GBUniversity of Southampton · GB

Funding

Biotechnology and Biological Sciences Research Council BB/K011502/1Cancer Research UK 24721Cancer Research UK A20537
6 · The paper itself

Abstract

Fc γ receptors (FcγR) are involved in multiple aspects of immune cell regulation, are central to the success of mAb therapeutics, and underpin the pathology of several autoimmune diseases. However, reliable assays capable of accurately measuring FcγR interactions with their physiological ligands, IgG immune complexes (IC), are limited. A method to study and detect IC interactions with FcγRs was therefore developed. This method, designed to model the signaling pathway of the inhibitory FcγRIIB (CD32B), used NanoLuc Binary Interaction Technology to measure recruitment of the Src homology 2 domain-containing inositol phosphatase 1 to the ITIM of this receptor. Such recruitment required prior cross-linking of an ITAM-containing activatory receptor, and evoked luciferase activity in discrete clusters at the cell surface, recapitulating the known biology of CD32B signaling. The assay detected varying forms of experimental IC, including heat-aggregated IgG, rituximab-anti-idiotype complexes, and anti-trinitrophenol-trinitrophenol complexes in a sensitive manner (≤1 μg/ml), and discriminated between complexes of varying size and isotype. Proof-of-concept for the detection of circulating ICs in autoimmune disease was provided, as responses to sera from patients with systemic lupus erythematosus and rheumatoid arthritis were detected in small pilot studies. Finally, the method was translated to a stable cell line system. In conclusion, a rapid and robust method for the detection of IC was developed, which has numerous potential applications including the monitoring of IC in autoimmune diseases and the study of underlying FcγR biology.

Indexed as

Antigen-Antibody ComplexArthritis, RheumatoidAutoimmune DiseasesCell LineHEK293 CellsHumansImmunoglobulin GLupus Erythematosus, SystemicPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesPhosphoproteinsReceptors, IgGRituximabSignal Transductionsrc Homology DomainsAntigen-Antibody ComplexFc gamma receptor IIBFCGR2B protein, humanImmunoglobulin GINPP5D protein, humanPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesPhosphoproteinsReceptors, IgGRituximab

Identifiers

PMID29351998
PMCPMC5837011
OpenAlexW2782652020

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.